Questcor Pharmaceuticals (QCOR) 91.20 $QCOR
Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 6:45PM CDT
The broader market may suffer through its tumultuous one- or two-day pullbacks now and then, but the fact that three-out-of-eight stocks are within 10% or less of a fresh 52-week high demonstrates how resilient this market has been. For skeptics like...
Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 38.4% (QCOR)
Comtex SmarTrend(R) - Thu May 22, 9:36AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 38.41% as of today's recent price of $93.30.
Senior Level Appointments, Collaboration Agreements, Prestigious Awards Nominations, and Company Updates - Analyst Notes on Biogen Idec, Questcor, Zimmer, Cigna and Ctrip.com
PR Newswire - Thu May 22, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Zimmer Holdings, Inc. (NYSE: ZMH), Cigna Corporation (NYSE: CI) and Ctrip.com International Ltd. (NASDAQ: CTRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2808-100free.
Downgrade Alert for Questcor Pharmaceuticals (QCOR)
Comtex SmarTrend(R) - Tue May 20, 6:56AM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $92.08 on volume of 2.0 million shares, below average daily volume of 3.5 million. Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company's primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions.
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology
PR Newswire - Tue May 20, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Puma Biotechnology, Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2665-100free.
SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.80% Gain
Comtex SmarTrend(R) - Fri May 16, 4:18PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.28 to a high of $90.93. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $88.94 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri May 16, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Shares of QCOR Up 30.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 15, 9:11AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 1 month, Questcor Pharmaceuticals has returned 30.01% as of today's recent price of $87.64.
Questcor (QCOR) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 15, 8:00AM CDT
Questcor (QCOR) is Overbought: Is A Drop Coming?
Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides
PR Newswire - Wed May 14, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen®, this transaction significantly expands Questcor's portfolio of melanocortin therapeutics and further establishes the company as the leader in this important emerging field of medicine.
Post Earnings Update: Questcor Pharmaceuticals Has Climbed 10.5% Higher in Past 2 Weeks (QCOR)
Comtex SmarTrend(R) - Mon May 12, 11:42AM CDT
When Questcor Pharmaceuticals (NASDAQ:QCOR) reported earnings 14 days ago on April 28th, 2014, analysts, on average, expected the company to report earnings of $1.61 on sales of $240.8 million. Questcor Pharmaceuticals actually reported earnings of $1.51 per share on sales of $227.1 million, missing EPS estimates by $0.10 and missing revenue estimates by $13.6 million. Since the company's report, shares of Questcor Pharmaceuticals have risen from $79.05 to $87.34, representing a gain of 10.5% in the past 14 days.
Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period
Business Wire - Mon May 12, 6:01AM CDT
Mallinckrodt plc (NYSE: MNK), and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"
, in connection with Mallinckrodt's proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014.
Webcast Schedules, Clinical Study Results, Stock Price Movements, and Grants - Analyst Notes on Illumina, Questcor, Quest Diagnostics, Raytheon and Lockheed Martin
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Quest Diagnostics Inc. (NYSE: DGX), Raytheon Co. (NYSE: RTN) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2321-100free.
Scanning Equities that Reached New highs -- Research on Energy Transfer Equity, Questcor Pharma, Health Net, and Molson Coors Brewing
PR Newswire - Thu May 08, 12:30PM CDT
The markets on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished the day at 16,518.54, up 0.72%, and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the session 0.56% higher at 1,878.21. The gains were broad based as eight out of ten sectors ended the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Energy Transfer Equity L.P. (NYSE: ETE), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Health Net Inc. (NYSE: HNT) and Molson Coors Brewing Company (NASDAQ: TAP). Free technical research on ETE, QCOR, HNT and TAP can be downloaded upon signing up at:
Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results; Increases Full-Year 2014 Guidance
Business Wire - Thu May 08, 5:01AM CDT
--Increases guidance on full-year revenue and full-year adjusted diluted earnings per share reflecting strength of base business and acquisition of Cadence
After Yesterday's Rally of 2.53% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed May 07, 5:17PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $83.51 to a high of $86.51. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $85.00 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Akorn Q1 EPS Beats, Raises Full-Year Profit Outlook
at Investor's Business Daily - Tue May 06, 11:11AM CDT
Specialty drugmaker Akorn (AKRX) on Tuesday reported first-quarter EPS above views, but revenue was light. The company also raised its full-year profit outlook. Lake Forest, Ill.-based Akorn said that it earned 16 cents per share in the three months...
Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 6:45PM CDT
The broader market may suffer through its tumultuous one- or two-day pullbacks now and then, but the fact that three-out-of-eight stocks are within 10% or less of a fresh 52-week high demonstrates how resilient this market has been. For skeptics like...
Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 38.4% (QCOR)
Comtex SmarTrend(R) - Thu May 22, 9:36AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 38.41% as of today's recent price of $93.30.
Senior Level Appointments, Collaboration Agreements, Prestigious Awards Nominations, and Company Updates - Analyst Notes on Biogen Idec, Questcor, Zimmer, Cigna and Ctrip.com
PR Newswire - Thu May 22, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Zimmer Holdings, Inc. (NYSE: ZMH), Cigna Corporation (NYSE: CI) and Ctrip.com International Ltd. (NASDAQ: CTRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2808-100free.
Downgrade Alert for Questcor Pharmaceuticals (QCOR)
Comtex SmarTrend(R) - Tue May 20, 6:56AM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $92.08 on volume of 2.0 million shares, below average daily volume of 3.5 million. Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company's primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions.
Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology
PR Newswire - Tue May 20, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Puma Biotechnology, Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2665-100free.
SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.80% Gain
Comtex SmarTrend(R) - Fri May 16, 4:18PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.28 to a high of $90.93. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $88.94 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri May 16, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Shares of QCOR Up 30.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 15, 9:11AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 1 month, Questcor Pharmaceuticals has returned 30.01% as of today's recent price of $87.64.
Questcor (QCOR) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 15, 8:00AM CDT
Questcor (QCOR) is Overbought: Is A Drop Coming?
Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides
PR Newswire - Wed May 14, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen®, this transaction significantly expands Questcor's portfolio of melanocortin therapeutics and further establishes the company as the leader in this important emerging field of medicine.
Post Earnings Update: Questcor Pharmaceuticals Has Climbed 10.5% Higher in Past 2 Weeks (QCOR)
Comtex SmarTrend(R) - Mon May 12, 11:42AM CDT
When Questcor Pharmaceuticals (NASDAQ:QCOR) reported earnings 14 days ago on April 28th, 2014, analysts, on average, expected the company to report earnings of $1.61 on sales of $240.8 million. Questcor Pharmaceuticals actually reported earnings of $1.51 per share on sales of $227.1 million, missing EPS estimates by $0.10 and missing revenue estimates by $13.6 million. Since the company's report, shares of Questcor Pharmaceuticals have risen from $79.05 to $87.34, representing a gain of 10.5% in the past 14 days.
Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period
Business Wire - Mon May 12, 6:01AM CDT
Mallinckrodt plc (NYSE: MNK), and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"
, in connection with Mallinckrodt's proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014. Webcast Schedules, Clinical Study Results, Stock Price Movements, and Grants - Analyst Notes on Illumina, Questcor, Quest Diagnostics, Raytheon and Lockheed Martin
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Quest Diagnostics Inc. (NYSE: DGX), Raytheon Co. (NYSE: RTN) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2321-100free.
Scanning Equities that Reached New highs -- Research on Energy Transfer Equity, Questcor Pharma, Health Net, and Molson Coors Brewing
PR Newswire - Thu May 08, 12:30PM CDT
The markets on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished the day at 16,518.54, up 0.72%, and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the session 0.56% higher at 1,878.21. The gains were broad based as eight out of ten sectors ended the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Energy Transfer Equity L.P. (NYSE: ETE), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Health Net Inc. (NYSE: HNT) and Molson Coors Brewing Company (NASDAQ: TAP). Free technical research on ETE, QCOR, HNT and TAP can be downloaded upon signing up at:
Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Mallinckrodt plc Reports Fiscal 2014 Second Quarter Financial Results; Increases Full-Year 2014 Guidance
Business Wire - Thu May 08, 5:01AM CDT
--Increases guidance on full-year revenue and full-year adjusted diluted earnings per share reflecting strength of base business and acquisition of Cadence
After Yesterday's Rally of 2.53% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Wed May 07, 5:17PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $83.51 to a high of $86.51. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $85.00 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Akorn Q1 EPS Beats, Raises Full-Year Profit Outlook
at Investor's Business Daily - Tue May 06, 11:11AM CDT
Specialty drugmaker Akorn (AKRX) on Tuesday reported first-quarter EPS above views, but revenue was light. The company also raised its full-year profit outlook. Lake Forest, Ill.-based Akorn said that it earned 16 cents per share in the three months...
